Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial

Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial

Background Immune checkpoint inhibitors have shown minimal clinical activity in hormone receptor-positive metastatic breast cancer (HR+mBC). Doxorubicin and low-dose cyclophosphamide are reported to induce immune responses and counter regulatory T cells (Tregs). Here, we report the efficacy and safe...

Full description

Bibliographic Details
Main Authors: Ragnhild Sørum Falk, Bjornar Gilje, Andrea Gombos, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Beate Boge, Randi R. Mathiesen, Lars Julsrud, Øystein Garred, Hege G. Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire Dunn, Bjørn Naume, Jon Amund Kyte
Format: Article
Language:English
Published: BMJ Publishing Group 2024-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/1/e007990.full

Internet

https://jitc.bmj.com/content/12/1/e007990.full

Similar Items